Framework for the acceptability of technological health innovations [25]. ‌ Wezzie S. Lora (18139765)

Խորագրեր:

Comparative matrix: summary of Ag-RDT acceptability across countries. ‌ Wezzie S. Lora (18139765)

Խորագրեր:

Attributes of interviews (N = 228). ‌ Wezzie S. Lora (18139765)

Խորագրեր:

Signal strength of ADE at the drug level ranked by reports. ‌ Jun Hua Lai (22676523)

Խորագրեր:

Outcomes distribution of drug patients with the top 50 positive signal frequency by 4 methods (ROR PRR IC MGPS). ‌ Jun Hua Lai (22676523)

Խորագրեր:

Time-to-onset analysis using the Weibull distribution test. ‌ Jun Hua Lai (22676523)

Խորագրեր:

Characteristics of AEs reports. ‌ Jun Hua Lai (22676523)

Խորագրեր:

Top 50 drugs sorted by frequency of positive signals stratified by reporter – by 4 methods (ROR PRR IC MGPS). ‌ Jun Hua Lai (22676523)

Խորագրեր:

Gender Difference analysis of the top 50 drugs ranked by frequency by four methods (ROR PRR IC MGPS). ‌ Jun Hua Lai (22676523)

Խորագրեր:

Top 50 Drugs with positive signals by frequency – by four methods (ROR PRR IC MGPS). ‌ Jun Hua Lai (22676523)

Խորագրեր:

Two-by-two contingency table for disproportionality analysis. ‌ Jun Hua Lai (22676523)

Խորագրեր:

The top 50 drugs by frequency of positive signals stratified by sex – by 4 methods (ROR PRR IC MGPS). ‌ Jun Hua Lai (22676523)

Խորագրեր:

Flowchart. ‌ Jun Hua Lai (22676523)

Խորագրեր:

The top 25 drugs sorted by frequency of positive signals stratified by age – by 4 methods (ROR PRR IC MGPS). ‌ Jun Hua Lai (22676523)

Խորագրեր:

The principles of disproportionate measurement and the criteria for signal detection. ‌ Jun Hua Lai (22676523)

Խորագրեր: